We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current NANO market cap is 256.64M. The company's latest EPS is EUR -1.2102 and P/E is -4.50.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 3.48M | 2.54M | 2.51M | 2.65M | 4.78M |
| Operating Income | -30.07M | -46.67M | -36.39M | -52.51M | -46.47M |
| Net Income | -30.35M | -50.92M | -33.59M | -47M | -57.04M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 46.2M | 56.21M | 134.03M | 101.77M | 59.77M |
| Total Liabilities | 31.95M | 58.11M | 63.56M | 74.98M | 86.81M |
| Total Equity | 14.24M | -1.91M | 70.47M | 26.79M | -27.05M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -25.99M | -41.17M | -27.54M | -29.87M | -37.1M |
| Investing | 71k | -1.46M | -111k | -242k | 137k |
| Financing | 14.85M | 41.49M | 111.77M | -5.18M | -5.65M |
| Market Cap | 256.64M |
| Price to Earnings Ratio | -4.50 |
| Price to Sales Ratio | 53.7 |
| Price to Cash Ratio | 6.2 |
| Price to Book Ratio | -9.48 |
| Dividend Yield | - |
| Shares Outstanding | 47.13M |
| Average Volume (1 week) | 34.66k |
| Average Volume (1 Month) | 39.81k |
| 52 Week Change | 194.96% |
| 52 Week High | 10.40 |
| 52 Week Low | 1.618 |
| Spread (Intraday) | 0.08 (1.47%) |
| Company Name | Nanobiotix |
| Address |
batiment b 60 rue de wattignies paris, paris 75012 |
| Website | https://www.nanobiotix.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
